Trump Administration's Overhaul of Federal Grantmaking: Impacts on Pharma
Decision brief
Answer first · skim in under a minute
The Trump administration's proposed overhaul of the federal grantmaking process raises concerns among researchers. This article explores the potential impacts on the pharmaceutical industry.
Federal discretionary grantmaking is under tighter political review after an August 7, 2025 executive order. For pharma and biotech teams that depend on NIH and other HHS awards, the practical questions are award timing, termination risk, and how peer review now interacts with appointee oversight.
Contents9 sections
Key Takeaways
- August 7, 2025 EO: political appointees evaluate discretionary grant awards for alignment with priorities.
- Reuters (June 16, 2025): ~2,100 NIH grants (~$9.5B) and ~$2.6B in contracts reported terminated since January 2025.
- NIH Simplified Review Framework still governs many RPG applications from January 25, 2025 due dates (NOT-OD-24-010).
- Pharma BD should model funding pause and termination-for-convenience risk into academic and SBIR partnerships.
What did the Trump grantmaking executive order require?
On August 7, 2025, President Donald Trump signed an executive order to tighten federal grant approvals. Award decisions are to undergo evaluation by political appointees, with subject-matter experts also involved, and discretionary awards expected to advance presidential policy priorities where applicable.
Reuters coverage of the August 7 order states the White House framed the change as stronger oversight of grant spending, while rights advocates warned about political interference in academic research funding.
How large are the NIH funding disruptions so far?
Biomedical research funding is the most direct pharma-adjacent channel. In a June 16, 2025 report, Reuters wrote that a federal judge in Boston called certain NIH terminations of diversity-related grants “void and illegal,” and cited a letter from dozens of NIH employees stating that about 2,100 research grants totaling roughly $9.5 billion and an additional $2.6 billion in contracts had been terminated since Trump took office.
Those figures come from the employee letter summarized by Reuters’ healthcare desk; they are not independently audited in this article. Litigation outcomes can reinstate some awards while other topic-based terminations continue.
Where does NIH peer review still fit?
Operational NIH peer review did not disappear. NIH Guide Notice NOT-OD-24-010 announces a Simplified Review Framework for most research project grant applications beginning with due dates on or after January 25, 2025, reorganizing review around importance of the research and feasibility/rigor.
- Effective for listed RPG activity codes (including R01, R21, U01 and others in the notice).
- Goal stated by NIH: focus reviewers on whether the project should and can be conducted.
- Later notices (for example NOT-OD-25-135) describe centralization of peer review within the Center for Scientific Review.
Applicants should still follow the current instructions on grants.nih.gov NOT-OD-24-010 while monitoring agency-level political review layers created by the August 2025 order.
Implications for pharma BD, medical affairs, and academic alliances
Sponsors that fund investigator-initiated trials through university NIH awards should update diligence checklists: confirm active award status, termination clauses, and contingency budgets if a project loses federal support mid-stream. SBIR/STTR partners face similar cash-flow risk if notices of funding opportunity slow or advisory-council cycles slip.
Medical affairs and HEOR teams that rely on NIH-funded real-world evidence should track which disease areas remain prioritized. Earlier Reuters reporting also documented temporary freezes and Federal Register notice delays that slowed NIH grant cycles in early 2025—signals that calendar risk can matter as much as scientific score.
What remains unproven
This analysis does not claim a single final OMB rule text is in force for every agency as of publication. Proposed Uniform Guidance revisions and agency-specific implementations continue to move. Readers should verify the active award terms and any Federal Register final rules before assuming termination-for-convenience language applies to a specific grant.
Related NovaPharma coverage
- Senior NIH official pushes MAHA strategy to skeptical ADA audience
- Civil service protections impact at HHS, FDA, NIH, CDC
- RFK Jr.’s second year: Vacancies and Schedule F at NIH
Frequently Asked Questions
What did the August 2025 grantmaking executive order change?
On August 7, 2025, President Trump signed an executive order directing that discretionary federal grant awards undergo evaluation by political appointees so awards align with agency priorities and the national interest, according to Reuters reporting of the White House announcement.
How has NIH grant activity been affected?
A June 16, 2025 Reuters report cited NIH employee correspondence stating that about 2,100 research grants totaling roughly $9.5 billion, plus about $2.6 billion in contracts, had been terminated since Trump took office, alongside litigation over diversity-related grant cuts.
What NIH peer-review framework still applies to applicants?
Separately from political oversight debates, NIH implemented a Simplified Review Framework for most research project grant applications with due dates on or after January 25, 2025, as described in NIH Guide Notice NOT-OD-24-010.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
